Abstract
On March 9 2020 the WHO Global Influenza Program (GIP) asked participant sites on the Global Influenza Hospital Surveillance Network (GIHSN) to contribute to data collection concerning severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We re-analysed 5,833 viral RNA archived samples collected prospectively from hospital admissions for influenza-like illness (ILI) in the Valencia Region of Spain by the VAHNSI network (4 hospitals, catchment area population 1,118,732) during the prepandemic 2018/2019 (n=4,010) and pandemic 2019/2020 (n=1,823) influenza seasons, for the presence of SARS-CoV-2. We did not find evidence for community-acquired SARS-CoV-2 infection in hospital admissions for ILI in our region before early March 2020.
Competing Interest Statement
Dr. LOPEZ-LABRADOR reports the work in FISABIO-Public Health was partly funded by Sanofi Pasteur. Sanofi Pasteur did not participate in the design, conduct of the study, analysis or decision to publish the results. Dr. Mengual-Chulia reports grants from Sanofi Pasteur, during the conduct of the study. Dr. Mira-Iglesias reports other from Sanofi Pasteur, during the conduct of the study; other from Sanofi Pasteur, outside the submitted work. Dr. DIEZ-DOMINGO reports grants from SANOFI-PASTEUR, during the conduct of the study; and SP supported teaching activities from my institution.
Funding Statement
FXLL and BMC are supported by the CIBEResp, Instituto de Salud Carlos III, Spain. Data collection was partially supported by a grant from the Foundation for Influenza Epidemiology (FIE), which supports the Global Influenza Hospital Surveillance Network (see www.gihsn.org for more details). The sponsor did not participate in the study design, data analysis and interpretation, in the writing of the manuscript or in the decision to submit the manuscript for publishing.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Research Committee of the Direccion General de Salud Publica-Centro Superior de Investigacion en Salud Publica (DGSP-CSISP) previously approved the protocol for the study of respiratory viruses in the VANSHI network.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵& Both authors act as senior authors.
## Members of the VAHNSI network listed at the end of the manuscript.
Data Availability
Data is available under reasonable request
